Engene reports inducement grants under nasdaq listing rule 5635(c)(4)

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, “engene” or the “company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to four newly-hired employees, including amy pott, chief global commercialization officer, with a grant date of june 16, 2025. the inducement award for ms. pott consists of a non-qualified stock option to purchase an aggregate 400,000 of the company's common shares. the inducement awards fo.
ENGN Ratings Summary
ENGN Quant Ranking